Page 17 - SOGIBA 1 2020

Efecto de los tratamientos adicionales combinados con terapias convencionales...

BS, Mulla ZD. Elevated antiphospholipid antibody classification criteria for definite antiphospholipid
titers and adverse pregnancy outcomes: analysis syndrome (APS). J Thromb Haemost 2006;4
of a population-based hospital dataset. BMC Preg- (02):295–306
nancy Childbirth 2009;9:11 • Tincani A, Allegri F, Balestrieri G, et al. Minimal
• Simchen MJ, Dulitzki M, Rofe G, et al. High positi- requirements for antiphospholipid antibodies
ve antibody titers and adverse pregnancy outcome ELISAs proposed by the Euro- pean Forum on
in women with antiphospholipid syndrome. Acta antiphospholipid antibodies. Thromb Res 2004;
Obstet Gynecol Scand 2011;90(12):1428–1433 114(5-6):553–558
• Lima F, Khamashta MA, Buchanan NM, Kerslake • Reber G, Tincani A, Sanmarco M, de Moerloose P,
S, Hunt BJ, Hughes GR. A study of sixty pregnan- Boffa MC; Standardization Group of the European
cies in patients with the antipho- spholipid syn- Forum on Antiphospho- lipid Antibodies. Propo-
drome. Clin Exp Rheumatol 1996;14(02):131–136 sals for the measurement of anti-beta2- glycopro-
• Bramham K, Hunt BJ, Germain S, et al. Pregnancy tein I antibodies. Standardization group of the
outcome in different clinical phenotypes of anti- European Forum on Antiphospholipid Antibodies.
phospholipid syndrome. Lupus 2010;19(01):58–64 J Thromb Haemost 2004; 2(10):1860–1862
• de Jesús GR, Rodrigues G, de Jesús NR, Levy • Brandt JT, Triplett DA, Alving B, Scharrer I.
RA. Pregnancy morbidity in antiphospholipid Criteria for the diagnosis of lupus anticoagulant.
syndrome: what is the impact of treatment? Curr Thromb Haemost 1995;74 (04):1185–1190
Rheumatol Rep 2014;16(02):403 • Pengo V, Tripodi A, Reber G, et al; Subcommittee
• Bowman ZS, Wünsche V, Porter TF, Silver RM, on Lupus Anticoagulant/Antiphospholipid Anti-
• Ruffatti A, Tonello M, Cavazzana A, Bagatella P, Branch DW. Prevalence of antiphospholipid an- body of the Scientific and Standardisation Com-
Pengo V. Labora- tory classification categories and tibodies and risk of subsequent adverse obstetric mittee of the International Society on Thrombosis
pregnancy outcome in patients with primary anti- outcomes in women with prior pregnancy loss. J and Haemostasis. Update of the guidelines for
phospholipid syndrome prescribed antithrom- bo- Reprod Immunol 2015;107:59–63 lupus anticoagulant detection. J Thromb Haemost
tic therapy. Thromb Res 2009;123(03):482–487 • Danowski A, de Azevedo MN, de Souza Papi JA, 2009;7(10): 1737–1740
• Ruffatti A, Tonello M, Visentin MS, et al. Risk Petri M. Determi- nants of risk for venous and • Mekinian A, Lazzaroni MG, Kuzenko A, et al; SNF-
factors for pregnancy failure in patients with anti- arterial thrombosis in primary antiphospholipid MI and the European Forum on Antiphospholipid
phospholipid syndrome treated with conventional syndrome and in antiphospholipid syndrome Antibodies. The efficacy of hydroxychloroquine for
therapies: a multicentre, case-control study. Rheu- with systemic lupus erythematosus. J Rheumatol obstetrical outcome in anti-phospholipid syndro-
matology (Oxford) 2011;50(09):1684–1689 2009;36(06): 1195–1199 me: Data from a European multicenter retrospec-
• Latino JO, Udry S, Aranda FM, Perés Wingeyer • Ruffatti A, Hoxha A, Favaro M, et al. Additional tive study. Autoimmun Rev 2015;14(06):498–502
SDA, Fernández Romero DS, de Larrañaga GF. treatments for high-risk obstetric antiphospholi- • Sciascia S, Hunt BJ, Talavera-Garcia E, Lliso G,
Pregnancy failure in patients with obstetric anti- pid syndrome: a comprehensive review. Clin Rev Khamashta MA, Cuadrado MJ. The impact of hy-
phospholipid syndrome with conventional treat- Allergy Immunol 2017;53(01):28–39 droxychloroquine treatment on pregnancy outco-
ment: the influence of a triple positive antibody • Ruffatti A, Salvan E, Del Ross T, et al. Treatment me in women with antiphospholipid antibodies.
profile. Lupus 2017;26(09):983–988 strategies and pregnancy outcomes in antiphos- Am J Obstet Gynecol 2016;214(02):273.e1–273.e8

• Lockshin MD, Kim M, Laskin CA, et al. Prediction pholipid syndrome patients with thrombosis and • Kaplan YC, Ozsarfati J, Nickel C, Koren G. Repro-
of adverse pregnancy outcome by the presence triple antiphospholipid positivity. A European ductive outcomes following hydroxychloroquine
of lupus anticoagulant, but not anticardiolipin multicentre retrospective study. Thromb Haemost use for autoimmune diseases: a systematic review
antibody, in patients with antiphospholipid anti- 2014;112(04): 727–735 and meta-analysis. Br J Clin Pharmacol 2016;81
bodies. Arthritis Rheum 2012;64(07):2311–2318 • Miyakis S, Lockshin MD, Atsumi T, et al. Inter- (05):835–848
• Nodler J, Moolamalla SR, Ledger EM, Nuwayhid national consensus statement on an update of the • Cherin P, Marie I, Michallet M, et al. Management

Volumen 99 - Nº 1007 - Agosto 2020 15